Immune Escape after Hematopoietic Stem Cell Transplantation (HSCT): From Mechanisms to Novel Therapies

• Published in: Cancers 2019-12, Vol.12 (1), p.69
• Main Authors: Bernasconi, Paolo, Borsani, Oscar
• Format: Article
• Language: English
• Subjects: Acute myeloid leukemia; Antigens; Chemotherapy; Cytokines; Genes; Hematopoietic stem cells; Histocompatibility antigen HLA; Immune checkpoint; Immune evasion; Immune response; Immunology; Immunotherapy; Inflammation; Leukemia; Lymphocytes; Myeloid leukemia; Review; Risk groups; Stem cell transplantation; Stem cells; Transplants & implants
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers12010069

Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. Recent advances in understanding its molecular basis have opened the way to new therapeutic strategies, including targeted therapies. However, despite an improvement in prognosis it has been documented in recent years (especially in younger patients) that allogenic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative treatment in AML and the first therapeutic option for high-risk patients. After allo-HSCT, relapse is still a major complication, and is observed in about 50% of patients. Current evidence suggests that relapse is not due to clonal evolution, but instead to the ability of the AML cell population to escape immune control by a variety of mechanisms including the altered expression of HLA-molecules, production of anti-inflammatory cytokines, relevant metabolic changes and expression of immune checkpoint (ICP) inhibitors capable of "switching-off" the immune response against leukemic cells. Here, we review the main mechanisms of immune escape and identify potential strategies to overcome these mechanisms.